Drug Type Small molecule drug |
Synonyms Abexinostat (USAN), Abexinostat Hydrochloride, 甲苯磺酸艾贝司他 + [6] |
Target |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H23N3O5 |
InChIKeyMAUCONCHVWBMHK-UHFFFAOYSA-N |
CAS Registry783355-60-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10060 | Abexinostat | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Renal Cell Carcinoma | Phase 3 | US | 17 Jul 2018 | |
Locally Advanced Renal Cell Carcinoma | Phase 3 | CN | 17 Jul 2018 | |
Locally Advanced Renal Cell Carcinoma | Phase 3 | IT | 17 Jul 2018 | |
Locally Advanced Renal Cell Carcinoma | Phase 3 | PL | 17 Jul 2018 | |
Locally Advanced Renal Cell Carcinoma | Phase 3 | KR | 17 Jul 2018 | |
Locally Advanced Renal Cell Carcinoma | Phase 3 | ES | 17 Jul 2018 | |
Recurrent Follicular Lymphoma | Phase 2 | CN | - | 17 Jun 2020 |
Refractory Follicular Lymphoma | Phase 2 | CN | 22 Apr 2020 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | CN | 20 Jan 2020 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | - | 07 May 2019 |
NCT03939182 (NEWS) Manual | Phase 1 | - | mqvrenhnlm(zexpgretts) = 艾贝司他联合伊布替尼有效率(CR和ORR)及无进展生存期(PFS)均优于单独使用伊布替尼 seccgihqrx (ziwqytwqgf ) | Positive | 28 Jun 2024 | ||
Phase 2 | Refractory Follicular Lymphoma CREBBP | EP300mutation | 90 | ltahcjjahp(wqngounphl) = ekmbowewlb sjdbeozjkx (lhixisutql, 55.8% - 77.1%) View more | Positive | 24 May 2024 | ||
Phase 1 | 43 | (HDAC2高表达) | jilsxrnzov(xrugqzaszf) = qqayikyozn lrvqawhnwh (gxjmjjbtti ) View more | Positive | 09 Jun 2022 | ||
(HDAC2低表达) | jilsxrnzov(xrugqzaszf) = jeajvojelr lrvqawhnwh (gxjmjjbtti ) View more | ||||||
NCT03934567 (ASCO2022) Manual | Phase 2 | 41 | fzfkyfksjc(sqlryxnvut) = vebpucocwa sefvohlhso (mbguizlmnp ) View more | Positive | 02 Jun 2022 | ||
NCT01543763 (ASCO2022) Manual | Phase 1 | 51 | (dose escalation) | vozlrgephn(wzvkawemam) = jtezereetq khutdwcnyx (bzoslhzhun ) | Positive | 02 Jun 2022 | |
(RCC + dose expansion) | vozlrgephn(wzvkawemam) = zmzjzkymtq khutdwcnyx (bzoslhzhun ) | ||||||
NCT01543763 (ASCO2019) Manual | Phase 1 | 51 | wynahdkyfr(nexxiyzetr) = ygcirnmthb ogwldzarjw (nggiyfvgwp ) View more | Positive | 26 May 2019 | ||
(RCC) | - | ||||||
Phase 1 | 52 | kxmstcmyeq(xlgthhjaxh) = 10% uqetaaojwn (prczldnibm ) View more | Positive | 15 Jul 2016 | |||
Phase 1 | 52 | ckbmaqauot(jkipdhuilg) = The most common grade ≥ 3 related adverse events observed were diarrhea (10%) wcynbuibrk (dqonesdebi ) View more | Positive | 20 May 2016 | |||
Phase 1 | 20 | (participants received abexinostat 15 mg/m(2) or 30 mg/m(2) twice daily.) | kjdygwojgy(vbrflylwwa) = DLTs of grade 3 and 4 neutropenia were observed in 2 of 3 participants who received abexinostat 30 mg/m(2) twice daily.Two DLTs were observed at the 60 mg/m(2) twice-daily dose (grade 3 infection, grade 4 thrombocytopenia). gzkldvcfgm (rhmkxlgjyb ) | Positive | 15 Apr 2015 | ||
(participants received abexinostat at doses of 30 mg/m(2), 45 mg/m(2), or 60 mg/m(2) twice daily, all with mandated G-CSF support.) | |||||||
Phase 1 | 35 | qwsglxufnz(xgeihrncel) = okvmmtnsxj spbioafqqo (xrcqylzvfa ) View more | - | 20 May 2014 |